JHC
BCAX

Jones Hill Capital’s Bicara Therapeutics BCAX Stock Holding History

Jones Hill Capital’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5M Sell
892,621
-367,515
-29% -$8.2M 5.63% 5
2026
Q1 		$25.1M Buy
+1,260,136
New +$21.7M 5.37% 7

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jones Hill Capital's BCAX Position: Q2 2026 in Review

Jones Hill Capital reduced its Bicara Therapeutics (BCAX) stake by 29% in Q2 2026, selling an estimated $8.2M and leaving 892,621 shares worth $26.5M. The position accounts for 5.63% of the portfolio, ranked #5.

Jones Hill Capital first reported a position in BCAX in Q1 2026 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Jones Hill Capital held 892,621 shares of Bicara Therapeutics worth $26.5M as of Q2 2026.
  • Jones Hill Capital sold 367,515 Bicara Therapeutics shares in Q2 2026, an estimated $8.2M.
  • Bicara Therapeutics made up 5.63% of Jones Hill Capital's portfolio in Q2 2026, its #5 holding.
  • Jones Hill Capital first reported a position in Bicara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Jones Hill Capital's 13F filing for Q2 2026, filed 13 Aug 2026.